Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.
Sign Up to like & getrecommendations! Published in 2020 at "Thrombosis and haemostasis"
DOI: 10.1055/s-0040-1710315
Abstract: BACKGROUND  Emicizumab prophylaxis is a promising treatment that reduces bleeding events in severely affected patients with hemophilia A (PwHA). It is anticipated that emicizumab could be similarly effective in mild/moderate PwHA (PwMHA) although this effect… read more here.
Keywords: min1; improves vivo; emicizumab improves; pwmha ... See more keywords